Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults

BACKGROUND: In the ZOE-50 and ZOE-70 clinical trials, the candidate herpes-zoster subunit vaccine (HZ/su; 50µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) demonstrated high efficacy against HZ, with limited waning over 4 years and consistent efficacy across age cohorts. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauksens, Karlis, Volpe, Stephanie, Schwarz, Tino F, Smetana, Jan, Toursarkissian, Nicole, Rombo, Lars, Ravault, Stéphanie, David, Marie-Pierre, Bastidas, Adriana, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631129/
http://dx.doi.org/10.1093/ofid/ofx163.1039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631129/
http://dx.doi.org/10.1093/ofid/ofx163.1039

Ejemplares similares